Roche to terminate agreement with PDL over daclizumab

Roche will terminate an agreement with PDL BioPharma to develop and commercialise experimental compound, daclizumab, as a longer-term maintenance therapy for organ transplant patients. The companies' co-development deal for the drug will formally end next May, PDL announced on Tuesday.

Roche's decision comes after the drugmaker conducted an internal review of its development programmes, PDL explained in a statement. Earlier this year, Roche terminated a co-development agreement for daclizumab as a potential asthma treatment.

PDL is collaborating with Biogen Idec in the development of daclizumab for multiple sclerosis and other indications.

To read more Top Story articles, click here.